hAPOE2

Nomenclature

C57BL/6Smoc-Apoetm4(hAPOE2)Smoc

Cat. NO.

NM-HU-190013

Strain State

Repository Live

Export PDF

Gene Summary

Gene Symbol
Apoe

Model Description

This APOE2 humanized mouse model was established by replacing the mouse Apoe gene coding exons and introns with the human APOE2 corresponding sequence by homologous recombination.
Research Application:Immune-related

Validation Data

image.png

Fig.1 Detection of APOE expression in brain and liver by RT-PCR. Mouse Apoe mRNA (193 bp) was detectable only in wild-type C57BL/6 mice but not in hAPOE knockin mice. Human APOE mRNA (207 bp) was detectable only in homozygous hAPOE2 knockin mice but not in wild-type mice. Tissue RNA was extracted from wild-type C57BL/6 mice (WT) and homozygous hAPOE2 knockin mice (HO) (n=5 per group, male, 7 weeks old), then cDNA libraries were synthesized by reverse transcription, followed by PCR with mRNA primers.

image.png

Fig.2 Detection of human APOE(A) and mouse APOE(B) expression in serum of WT C57BL/6 mice and HO hAPOE2 mice by ELISA.  Mouse APOE was exclusively detectable in wild-type C57BL/6 mice but not in hAPOE2 knockin mice, and human APOE was exclusively detectable in homozygous hAPOE2 knockin mice. Serum samples were collected from wild-type C57BL/6 mice and HO hAPOE2 mice (n=5 per group, male, 7 weeks old), and analyzed by ELISA with an anti-mAPOE ELISA kit and an anti-hAPOE ELISA kit. 

Abbr. HO, homozygous; WT, wild type.

image.png

Fig.3 Detection of human APOE(A) and mouse APOE(B) expression in brain of WT C57BL/6 mice and HO hAPOE2 mice by ELISA.  Mouse APOE was exclusively detectable in the brain of WT C57BL/6 mice but absent in hAPOE2 knockin mice. Human APOE was positively detectable in the brain of homozygous hAPOE2 knockin mice, although the kit exhibited non-specific detection in brain lysates of WT mice. Brain tissues lysates were collected from WT C57BL/6 mice and HO hAPOE2 mice (n=5 per group, male, 7 weeks old), and analyzed by ELISA with an anti-mAPOE ELISA kit and an anti-hAPOE ELISA kit. 

Abbr.  HO, homozygous; WT, wild type; N.D., not detectable.

image.png

Fig.4 Detection of human APOE(A) and mouse APOE(B) expression in liver of WT C57BL/6 mice and HO hAPOE2 mice by ELISA. Mouse APOE was exclusively detectable in the liver of WT C57BL/6 mice but absent in hAPOE2 knockin mice. Human APOE was positively detectable in the liver of homozygous hAPOE2 knockin mice, although the kit exhibited non-specific detection in liver lysates of WT mice. Liver tissues lysates were collected from WT C57BL/6 mice and HO hAPOE2 mice (n=5 per group, male, 7 weeks old), and analyzed by ELISA with an anti-mAPOE ELISA kit and an anti-hAPOE ELISA kit. 

Abbr. HO, homozygous; WT, wild type; N.D., not detectable.

image.png

Fig.3 Blood lipid profiles of hAPOE2 knockin mice. Homozygous hAPOE2 mice exhibited significantly elevated serum TG, T-CHO and LDL-C levels compared to wild-type C57BL/6 mice, indicating the lipid dysmetabolism in hAPOE2 knockin mice. Serum samples were collected from wild-type C57BL/6 mice and HO hAPOE2 mice (n=5 per group, male, 7 weeks old) to measure levels of (A) triglycerides (TG), (B) total cholesterol (T-CHO), (C) high-density lipoprotein cholesterol (HDL-C) and (D) low-density lipoprotein cholesterol (LDL-C (n=5 per group, Mean ± SEM, t-test, *p < 0.05, ***p < 0.001, ****p < 0.0001, ns, no significance). 

Abbr. HO, homozygous; WT, wild type.




You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more